- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01547455
Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery
Anti-inflammatory and Renoprotective Effect of Pretreatment Loading Dose Atorvastatin in CABG
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Acute kidney injury occurs up to 30% in cardiac surgery which influenced patients' mid-term and long-term outcomes. Furthermore, evidence shows patients who initiate renal placement therapy in hospital have higher mortality and morbility. The pathologies of Cardiac surgery-associated acute kidney injury (CSA-AKI) is not clear yet ,many researches find cardiopulmonary bypass is an independent risk factor in developing AKI, and inflammatory bursts during cardiopulmonary bypass (CPB) may play an important role in CSA-AKI.
Statins are reported to have anti-inflammatory reaction in many researches. In Some multicenter RCTS, Statins are reported to reduce myocardial infarction,atrial fibrillation and have renoprotective effects due to pleiotropic effects in percutaneous coronary intervention. While in the cardiac surgery settings, the renoprotective effect of statin is still controversial. The investigators believe the differences between surgery and PCI may contribute to the discrepancy. The investigators plan to test the renoprotective effect of atorvastatin in a randomized,double-blind control manner and try to explore the mechanism of this protective effect.
The investigators hypothesise loading dose atorvastatin pretreatment in elective coronary artery bypass grafting surgery may attenuate inflammatory response in CPB and therefore reduce postoperative AKI or help recovery from AKI.
The investigators randomize patients into two arms, the Atorvastatin group takes Atorvastatin 80mg 12h before surgery with another 40mg 2h before operation, the control arm takes placebo in the same regime. The investigators plan to compare the inflammatory cytokines at different time points and the incidence of AKI between the two groups. The investigators hope Atorvastatin group can decrease AKI incidence and has a lower level of inflammatory cytokines, what's more, the two have a good correlation in the time frame.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Beijing
-
Beijing, Beijing, Chine, 100037
- Cardiovascular Institute&Fuwai Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- age > 18 years old
- elective coronary artery bypass surgery in CPB
Exclusion Criteria:
- emergent surgery
- re-operation
- acute kidney dysfunction
- chronic kidney disease
- GFR < 60ml/min
- liver dysfunction
- existing myopathy
- LEVF < 40%
- statin allergic or contradictive
- pregnancy
- breast feed period
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Atorvastatin
participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
|
participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
Autres noms:
|
Comparateur placebo: Control
Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
|
Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
acute kidney injury
Délai: 72 hours after surgery
|
Proportion developing AKI using AKIN criteria(stage 1,stage 2, stage3).we
plan to measure serum creatinine in baseline, ICU admission,postoperative 6h、Day 1、Day 2 and Day 3.If multiple SCr was measured in one day ,then the highest value will be recorded.Also, we measure creatinine clearance via Cock-croft-Gault formula.
|
72 hours after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change of inflammatory biomarkers
Délai: 48h after surgery
|
we plan to measure IL-6,IL-10,TNF-α and hsCRP at 6 time points: before surgery、after chest closure、postOp.6h、12h、24h
and 48h.Compare levels of cytokines between the two arms
|
48h after surgery
|
Requirement of renal replacement therapy
Délai: participants will be followed for the duration of hospital stay , an expected average of 2 weeks
|
proportion need renal replacement therapy in hospital
|
participants will be followed for the duration of hospital stay , an expected average of 2 weeks
|
liver function
Délai: participants will be followed for the duration of hospital stay , an expected average of 2 weeks
|
liver dysfunction defined as transaminase>3UNL normal level
|
participants will be followed for the duration of hospital stay , an expected average of 2 weeks
|
death
Délai: 30 days after discharge from hospital
|
30 days after discharge from hospital
|
|
MACCE events
Délai: 30 days after discharge from hospital
|
30 days after discharge from hospital
|
|
length of stay in intensive care unit
Délai: From admission to discharge from ICU
|
An average of 2 days
|
From admission to discharge from ICU
|
length of stay in hospital after surgery
Délai: From surgery to discharge from hospital, an expected average of 7 days
|
From surgery to discharge from hospital, an expected average of 7 days
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Weipeng Wang, MD,PhD, Chinese Academy of Medical Sciences, Fuwai Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies rénales
- Maladies urologiques
- Insuffisance rénale
- Lésion rénale aiguë
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Antimétabolites
- Agents anticholestérolémiants
- Agents hypolipidémiants
- Agents de régulation des lipides
- Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase
- Atorvastatine
Autres numéros d'identification d'étude
- 2011-1002-007
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Lésion rénale aiguë
-
Kessler FoundationInstituto Vocacional Enrique Díaz de León A.C., Guadalajara, MexicoRecrutementTBI (Traumatic Brain Injury) ou MS (Sclérose en Plaques)États-Unis, Espagne
Essais cliniques sur Atorvastatin(Lipitor)
-
Dong-A ST Co., Ltd.InconnueEn bonne santéCorée, République de
-
CHU de Quebec-Universite LavalCanadian Institutes of Health Research (CIHR); BiovaloremRecrutementCancer du pancréas | Cancer métastatique | Adénocarcinome canalaire pancréatique | Cancer du pancréasCanada